University of Iowa Department of Psychiatry Lifespan Clinical Neuropsychology

APPCN MEMBER SINCE 2018

University of Iowa Department of Psychiatry Lifespan Clinical Neuropsychology
Program director name: Douglas Whiteside, PhD, ABPP
Mailing address: Department of Psychiatry, UIHC, 200 Hawkins Drive, Iowa City, IA 52242
Telephone #: 319-356-1103
Fax #: NA
E-mail address: douglas-whiteside@uiowa.edu 

For a detailed program description click on this link: https://medicine.uiowa.edu/psychiatry/education/fellowship-programs/postdoctoral-residency-lifespan-clinical-neuropsychology

Program will do interviews at INS in 2019: Yes
Policy regarding on-site interviews: Competitive applicants will be contacted and invited to interview with program faculty at INS. Applicants are encouraged to contact previous postdoctoral residents. 

2019 application deadline: December 17, 2018
2019 residency start date: August 1, 2019 (flexible if needed)

Clinical neuropsychology residency openings for 2019: 1
Clinical neuropsychology residency positions: 1
Residency/fellowship positions in psychology: N/A

Clinical neuropsychologists: 4 Full-time, 1 Part-time
With ABCN/ABPP: 2 Full-time; 1 Part-time
(please see webpage for faculty)

Other psychologists: 21
With ABPP: 1

Graduate training of residency applicants:

Preferred: Clinical Psychology, Counseling Psychology
Accepted: Neuropsychology, School Psychology
Not Accepted: Non-APA/CPA accredited programs

Primary emphasis: Lifespan Neuropsychology-Adults and Pediatrics

Emphases of training opportunities:

Strong: neuropsychological assessment, neuropsychological development, neuropsychological consultation, research, resident supervision of psychometrists and practicum students
Moderate: Cognitive Rehabilitation, medico-legal consultation
Weak: Psychotherapy

Availability of patient populations:

Strong: Neuropsychiatric disorders, dementia, traumatic brain injury, metabolic and other chronic health conditions, neurological disorders, oncology, organ transplant, and learning disorders/ADHD.
Moderate: multiple sclerosis, HIV
Weak: Wada testing

updated: 10/10/18